Subscribe Today

Get our free articles delivered directly to your email!

Continue reading

According to Bloomberg, Global Blood Therapeutics (GBT) Draws Takeover Interest

  • August 4, 2022


StockGlobal Blood Therapeutics, Inc.SymbolGBT
Date Announced08/04/2022Source Bloomberg
TypeNews Report
Date of Confirmation: 08/08/2022Price at Confirmation: $66.60
Potential Profit: 38.78%Annualized Profit: 3538.58%

Global Blood Therapeutics Inc., (GBT) which makes a drug for sickle cell disease, is attracting takeover interest, according to people familiar with the matter.


August 5, 2022: Pfizer Inc. (PFE) is in advanced talks to buy Global Blood Therapeutics Inc., (GBT) for about $5 billion, in the latest move by the drug giant to bolster its portfolio and pipeline.

August 8, 2022: Pfizer Inc. (PFE) has agreed to buy Global Blood Therapeutics Inc., (GBT) the maker of a drug for sickle-cell disease, in a deal worth $5.4 billion.

August 24, 2022: Pfizer Inc. (PFE) and Johnson & Johnson duked it out in a bidding war for Global Blood Therapeutics Inc. days before Pfizer won with a $5.4 billion offer this month, according to people familiar with the matter.

September 30, 2022:  Global Blood Therapeutics (GBT) expects to consummate its deal with Pfizer (PFE) on October 5, 2022.

Disclaimer: Our intent with this section of the website is to present potential deals that appear to be in the pipeline. These potential deals are ones where i) the company has indicated that it is "seeking strategic alternatives", ii) there has been an unsolicited bid for a company as mentioned in a press release by the company or iii) news about the deal has been published by a leading news organization like The Wall Street Journal, The New York Times, Bloomberg, Financial Times, The Washington Post, Reuters and The Associated Press. As best as possible we will try to avoid baseless rumors. There is a high probability that many of these potential deals may not materialize and if they do, the terms of the deal may be different from what was initially reported. Please do your own due diligence before buying or selling any securities mentioned on this website. We do not warrant the completeness or accuracy of the content or data provided.